Application of gallocatechin gallate in preparation of benign prostatic hyperplasia resistant medicament

A technology of gallocatechin and gallic acid ester, applied in the direction of drug combination, urinary system diseases, etc.

Inactive Publication Date: 2012-09-19
江苏凯吉生物科技有限公司 +1
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But there is no report that the monomer compound GCG is used to prepare anti-benign prostatic hyperplasia drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of gallocatechin gallate in preparation of benign prostatic hyperplasia resistant medicament
  • Application of gallocatechin gallate in preparation of benign prostatic hyperplasia resistant medicament
  • Application of gallocatechin gallate in preparation of benign prostatic hyperplasia resistant medicament

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1 Effect of gallocatechin gallate on rat prostate

[0022] 1. Experimental animals

[0023] Male healthy SD (Sprague-Dawley) rats, clean grade, weighing 250±20g, purchased from Shanghai Xipuer-Bikay Laboratory Animal Co., Ltd., certificate number: 00800160568, production license number: SCXK (Shanghai) 2008-0016 .

[0024] 2. Modeling, grouping and administration

[0025] The above-mentioned 35 rats were generally fed for one week to adapt to the environment. After ordinary observation showed no abnormalities, 7 animals were randomly selected as the normal control group, and the remaining 28 animals were used for modeling. After being anesthetized with ether, the skin was routinely disinfected under aseptic conditions, the bilateral testes were removed through the scrotum, the stump was ligated to ensure hemostasis, the skin was sutured, and a certain amount of ofloxacin injection was dripped to prevent infection. Intramuscular injection (im) penicillin 400,...

Embodiment 2

[0058] The preparation of embodiment 2 gallocatechin gallate liposomes

[0059] Dissolve lecithin, cholesterol and gallocatechin gallate in absolute ethanol and chloroform (the volume ratio of absolute ethanol and chloroform is 1: 1, and the total volume is 15ml) in a ratio of 3g: 1g: 0.1g by mass. Add 2 mg of vitamin E to the mixed solution to obtain solution A, dissolve 33 mg of folic acid in 330 μl dimethyl sulfoxide to obtain solution B, mix solutions A and B and add 9 g of lactose to obtain mixture C, remove the solvent from solution C to obtain Phospholipid film; the obtained phospholipid film is dissolved in water, liposomes are obtained after hydration, the liposomes are filtered through a 0.2 μm filter membrane, and the liposome solution is gradually mixed in a high-pressure homogenizer under a pressure of 200-400Mpa Step pressurized and homogenized for 2 hours, the obtained liposome was a clear and uniform solution. The obtained liposome solution was freeze-dried to...

Embodiment 3

[0061] The preparation of embodiment 3 gallocatechin gallate capsules

[0062] Prescription: 500 g of gallocatechin gallate, 15 g of starch, 5 g of magnesium stearate (about 0.5%), made into 1000 capsules.

[0063] Preparation: Pass gallocatechin gallate, starch and magnesium stearate through an 80-mesh sieve, mix them evenly, and put them into empty capsules to obtain the product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
encapsulation rateaaaaaaaaaa
Login to view more

Abstract

The invention discloses application of gallocatechin gallate in preparation of a benign prostatic hyperplasia resistant medicament. Influence on prostate weight and prostate indexes of a rat and pathological change of prostate tissues are observed through a testosterone propionate induced castrated rat prostatic hyperplasia model by using the gallocatechin gallate as a treatment medicament. Research results show that the gallocatechin gallate can remarkably reduce the prostate weight and the prostate index of a model animal and improve the pathological symptoms of the prostate tissues.

Description

technical field [0001] The invention belongs to the field of pharmacy and relates to a new medical application of gallocatechin gallate, in particular to the application of gallocatechin gallate in preparing anti-benign prostatic hyperplasia medicine. Background technique [0002] benign prostatic hyperplasia [1] (benign prostatic hyperplasia, BPH) is a common physiological lesion in elderly men, and its incidence has shown an obvious upward trend in recent years; according to statistics, the incidence of this disease in men over 60 years old is over 70%, seriously affecting the health of elderly patients and quality of life. Drugs clinically used to treat BPH mainly include [2] : α1-adrenoceptor antagonists, 5α-reductase inhibitors and natural product preparations, etc. Since natural product preparations have less adverse reactions and are suitable for long-term use, they have attracted widespread attention in recent years. [0003] The structural formula of gallocatech...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/353A61P13/08
Inventor 温尧林李鹏李坤
Owner 江苏凯吉生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap